Financials in USD. Standardized financial statements.
A compact view of how CanSino Biologics Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $1.03B | $824.88M | $345.18M | $1.03B | $4.30B | $24.89M | $2.28M | $1.13M | -$602,320 | $8.20M |
| Revenue Growth? | +25.1% | +139.0% | -66.5% | -76.0% | +17174.8% | +990.0% | +101.7% | +287.9% | -107.3% | 0.0% |
| Cost of Revenue? | $350.18M | $244.43M | $1.22B | $1.22B | $1.30B | $13.80M | $147,463 | $113.65M | $68.10M | $51.67M |
| Gross Profit? | $681.87M | $580.45M | -$876.02M | -$186.61M | $3.00B | $4.74M | $2.14M | -$112.51M | -$68.70M | -$43.47M |
| Gross Margin? | +66.1% | +70.4% | -253.8% | -18.1% | +69.8% | +19.0% | +93.5% | -9939.4% | +11406.3% | -530.5% |
| Operating Expenses? | $795.00M | $983.84M | $1.16B | $1.18B | $1.20B | $407.98M | $204.21M | $152.35M | $75.60M | $54.36M |
| Operating Income? | -$113.13M | -$403.39M | -$2.04B | -$1.37B | $1.94B | -$397.82M | -$200.25M | -$138.58M | -$63.80M | -$52.69M |
| EBITDA? | $60.98M | -$109.84M | -$1.65B | -$1.32B | $1.85B | -$498.75M | -$204.90M | -$126.26M | -$67.12M | -$45.13M |
| Income Before Tax | $21.18M | -$381.20M | -$1.98B | -$1.18B | $1.94B | -$396.64M | -$156.77M | -$138.28M | -$64.45M | -$49.85M |
| Income Tax Expense | -$5.98M | $2.47M | -$11.45M | -$219.24M | $29.70M | $0 | $39.82M | $0 | $0 | $0 |
| Net Income? | $27.15M | -$378.88M | -$1.48B | -$909.43M | $1.91B | -$396.64M | -$156.77M | -$138.28M | -$64.45M | -$49.85M |
| EPS? | $0.11 | $-1.53 | $-6.01 | $-3.69 | $7.74 | $-1.60 | $-0.63 | $-0.63 | $-0.30 | $-0.23 |
| Diluted EPS? | $0.11 | $-1.53 | $-6.01 | $-3.69 | $7.74 | $-1.60 | $-0.63 | $-0.88 | $-0.30 | $-0.23 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality